FAS and lung cancer: For example, Xu and colleagues reported reduced expression of CD95 (as well as some other activation- and cytotoxicity-related markers) by circulating CD3+CD8+Т lymphocytes from patients with advanced lung cancer and proposed this reduction might be linked to impairment of killer T-cell function [31].